Signet公司推出一系列临床检测新方法

两种新型检测方法可以检测腺苷脱氨酶结合蛋白，在脓毒血症与急性肾功能衰竭起病之前，这种蛋白在尿样本中的水平已经升高。 这些检测方法是做为脓毒败血症与急性肾功能衰竭的新型诊断/治疗方案而研发的，只做为研究之用。检测脓毒败血症的方法叫做ABP-26，检测急性肾功能衰竭的方法叫做Nephroscreen。设计这些检测方法的目的是为了比当前使用的诊断方法更早的检测并相应使用预防性治疗措施。这些检测方法都是美国Signet实验室研制的。 Signet的其它免疫病理诊断产品包括：P504，检测前列腺癌与前列腺活检标本中新生物病变的抗体辅助诊断方法；Acuity小鼠:小鼠聚合体检测系统，使用单克隆或者多克隆抗体检测小鼠或者大鼠组织的检测系统。Acutiy让研究者减少抗体用量、提高染色强度以及消除背景来降低成本， 在过去的一年中，Signet开发了一系列单克隆抗体、多克隆抗体以及酶联免疫吸附试剂盒用于检测癌症、感染性疾病以及神经退行性疾病。公司近期宣布扩大生产线，用于诊断性检测方法和抗体来检测与治疗严重的疾病。 Signet公司总裁兼首席执行光Richard Gill医生解释说：“我们的目标是继续创造新试剂与诊断方法，来预测疾病出现、研发治疗方法，做为临床实践的战胜疾病的可靠武器。” New Assays for Sepsis Two new assays measure levels of adenosine deaminase-binding protein (ADBP), which has been shown to rise in urine samples prior to onset of both sepsis and acute renal failure. The assays were developed as a new diagnostic/therapeutic regime for sepsis and acute renal failure (SARF) and both are for research use only. The assay for sepsis is called ABP-26, and the assay for acute renal failure is called Nephroscreen. They are designed to enable detection and the use of preventive therapy far earlier than current diagnostic regimes. The assays were developed by Signet Laboratories (Dedham, MA, USA). Other new immunopathology products from Signet include P504, an antibody aiding the diagnosis of prostate cancer and neoplastic changes in prostate biopsies; and the Acuity mouse-on-mouse polymer detection system, a system for use with monoclonal and polyclonal antibodies on mouse or rate tissue. Acuity provides cost savings by enabling researchers to use less antibody, while increasing staining intensity and eliminating background. Over the past year, Signet has launched an array of monoclonal and polyclonal antibodies and enzyme-linked immunosorbent assay (ELISA) kits for cancer, infectious disease, and neurodegenerative disease. The company has recently announced the expansion of its product line of diagnostic assays and antibodies for detecting and treating critical disease states. “Our goal is to continue to create new reagents and diagnostics that predict emergence of disease, and develop therapies as reliable preventive weapons against disease in clinical setting,” explained Dr. Richard Gill, president and CEO of Signet Labs.